ImmunoGen Touts Additional Positive Data From Ovarian Cancer Drug, Seeks Expanded Use Approval, Stock Soars – Yahoo Finance

by

  1. ImmunoGen Touts Additional Positive Data From Ovarian Cancer Drug, Seeks Expanded Use Approval, Stock Soars Yahoo Finance
  2. ImmunoGen Touts Additional Positive Data From Ovarian Cancer Drug, Seeks Expanded Use Approval, Stock Soa Benzinga
  3. ImmunoGen’s Elahere delivers landmark ovarian cancer win FiercePharma
  4. ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer Yahoo Finance
  5. Why ImmunoGen Stock Is Blasting Off Wednesday – Immunogen (NASDAQ:IMGN) Benzinga
  6. View Full Coverage on Google News

Read original article here

Leave a Comment